COVID-19 Impact on Drugs for Non-small Cell Lung Cancer Market, Global Research Reports 2020-2021

    • ID: AR2932968
    • 27 May, 2020
    • Other
    • Region: Global
    • 126 Pages
    • QYResearch

  • 1.1 Research Scope
  • 1.2 Market Segmentation
  • 1.3 Research Objectives
  • 1.4 Research Methodology
    • 1.4.1 Research Process
    • 1.4.2 Data Triangulation
    • 1.4.3 Research Approach
    • 1.4.4 Base Year
  • 1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
    • 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
    • 1.5.2 Covid-19 Impact: Commodity Prices Indices
    • 1.5.3 Covid-19 Impact: Global Major Government Policy
  • 1.6 The Covid-19 Impact on Drugs for Non-small Cell Lung Cancer Industry
  • 1.7 COVID-19 Impact: Drugs for Non-small Cell Lung Cancer Market Trends
  • 2 Global Drugs for Non-small Cell Lung Cancer Quarterly Market Size Analysis

    • 2.1 Drugs for Non-small Cell Lung Cancer Business Impact Assessment - COVID-19
      • 2.1.1 Global Drugs for Non-small Cell Lung Cancer Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
    • 2.2 Global Drugs for Non-small Cell Lung Cancer Quarterly Market Size 2020-2021
    • 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
      • 2.3.1 Drivers
      • 2.3.2 Restraints
      • 2.3.3 Opportunities
      • 2.3.4 Challenges

    3 Quarterly Competitive Assessment, 2020

    • 3.1 By Players, Global Drugs for Non-small Cell Lung Cancer Quarterly Market Size, 2019 VS 2020
    • 3.2 By Players, Drugs for Non-small Cell Lung Cancer Headquarters and Area Served
    • 3.3 Date of Key Players Enter into Drugs for Non-small Cell Lung Cancer Market
    • 3.4 Key Players Drugs for Non-small Cell Lung Cancer Product Offered
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Impact of Covid-19 on Drugs for Non-small Cell Lung Cancer Segments, By Type

    • 4.1 Introduction
      • 1.4.1 Radiofrequency Ablation (RFA)
      • 1.4.2 Radiation Therapy
      • 1.4.3 Chemotherapy
      • 1.4.4 Targeted Therapies
      • 1.4.5 Immunotherapy
    • 4.2 By Type, Global Drugs for Non-small Cell Lung Cancer Market Size, 2019-2021

    5 Impact of Covid-19 on Drugs for Non-small Cell Lung Cancer Segments, By Application

    • 5.1 Overview
      • 5.5.1 Hospitals
      • 5.5.2 Clinics
      • 5.5.3 Other
    • 5.2 By Application, Global Drugs for Non-small Cell Lung Cancer Market Size, 2019-2021
      • 5.2.1 By Application, Global Drugs for Non-small Cell Lung Cancer Market Size by Application, 2019-2021

    6 Geographic Analysis

    • 6.1 Introduction
    • 6.2 North America
      • 6.2.1 Macroeconomic Indicators of US
      • 6.2.2 US
      • 6.2.3 Canada
    • 6.3 Europe
      • 6.3.1 Macroeconomic Indicators of Europe
      • 6.3.2 Germany
      • 6.3.3 France
      • 6.3.4 UK
      • 6.3.5 Italy
    • 6.4 Asia-Pacific
      • 6.4.1 Macroeconomic Indicators of Asia-Pacific
      • 6.4.2 China
      • 6.4.3 Japan
      • 6.4.4 South Korea
      • 6.4.5 India
      • 6.4.6 ASEAN
    • 6.5 Rest of World
      • 6.5.1 Latin America
      • 6.5.2 Middle East and Africa

    7 Company Profiles

    • 7.1 Bristol-Myers Squibb
      • 7.1.1 Bristol-Myers Squibb Business Overview
      • 7.1.2 Bristol-Myers Squibb Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
      • 7.1.3 Bristol-Myers Squibb Drugs for Non-small Cell Lung Cancer Product Introduction
      • 7.1.4 Bristol-Myers Squibb Response to COVID-19 and Related Developments
    • 7.2 GlaxoSmithKline
      • 7.2.1 GlaxoSmithKline Business Overview
      • 7.2.2 GlaxoSmithKline Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
      • 7.2.3 GlaxoSmithKline Drugs for Non-small Cell Lung Cancer Product Introduction
      • 7.2.4 GlaxoSmithKline Response to COVID-19 and Related Developments
    • 7.3 Menarini
      • 7.3.1 Menarini Business Overview
      • 7.3.2 Menarini Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
      • 7.3.3 Menarini Drugs for Non-small Cell Lung Cancer Product Introduction
      • 7.3.4 Menarini Response to COVID-19 and Related Developments
    • 7.4 Sanofi
      • 7.4.1 Sanofi Business Overview
      • 7.4.2 Sanofi Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
      • 7.4.3 Sanofi Drugs for Non-small Cell Lung Cancer Product Introduction
      • 7.4.4 Sanofi Response to COVID-19 and Related Developments
    • 7.5 Ziopharm Oncology
      • 7.5.1 Ziopharm Oncology Business Overview
      • 7.5.2 Ziopharm Oncology Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
      • 7.5.3 Ziopharm Oncology Drugs for Non-small Cell Lung Cancer Product Introduction
      • 7.5.4 Ziopharm Oncology Response to COVID-19 and Related Developments
    • 7.6 Alchemia
      • 7.6.1 Alchemia Business Overview
      • 7.6.2 Alchemia Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
      • 7.6.3 Alchemia Drugs for Non-small Cell Lung Cancer Product Introduction
      • 7.6.4 Alchemia Response to COVID-19 and Related Developments
    • 7.7 Amgen
      • 7.7.1 Amgen Business Overview
      • 7.7.2 Amgen Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
      • 7.7.3 Amgen Drugs for Non-small Cell Lung Cancer Product Introduction
      • 7.7.4 Amgen Response to COVID-19 and Related Developments
    • 7.8 Apotex
      • 7.8.1 Apotex Business Overview
      • 7.8.2 Apotex Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
      • 7.8.3 Apotex Drugs for Non-small Cell Lung Cancer Product Introduction
      • 7.8.4 Apotex Response to COVID-19 and Related Developments
    • 7.9 BioMarin Pharmaceutical
      • 7.9.1 BioMarin Pharmaceutical Business Overview
      • 7.9.2 BioMarin Pharmaceutical Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
      • 7.9.3 BioMarin Pharmaceutical Drugs for Non-small Cell Lung Cancer Product Introduction
      • 7.9.4 BioMarin Pharmaceutical Response to COVID-19 and Related Developments
    • 7.10 CellAct Pharma
      • 7.10.1 CellAct Pharma Business Overview
      • 7.10.2 CellAct Pharma Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
      • 7.10.3 CellAct Pharma Drugs for Non-small Cell Lung Cancer Product Introduction
      • 7.10.4 CellAct Pharma Response to COVID-19 and Related Developments
    • 7.11 Cerulean Pharma
      • 7.11.1 Cerulean Pharma Business Overview
      • 7.11.2 Cerulean Pharma Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
      • 7.11.3 Cerulean Pharma Drugs for Non-small Cell Lung Cancer Product Introduction
      • 7.11.4 Cerulean Pharma Response to COVID-19 and Related Developments
    • 7.12 Cipla
      • 7.12.1 Cipla Business Overview
      • 7.12.2 Cipla Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
      • 7.12.3 Cipla Drugs for Non-small Cell Lung Cancer Product Introduction
      • 7.12.4 Cipla Response to COVID-19 and Related Developments
    • 7.13 Cornerstone Pharmaceuticals
      • 7.13.1 Cornerstone Pharmaceuticals Business Overview
      • 7.13.2 Cornerstone Pharmaceuticals Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
      • 7.13.3 Cornerstone Pharmaceuticals Drugs for Non-small Cell Lung Cancer Product Introduction
      • 7.13.4 Cornerstone Pharmaceuticals Response to COVID-19 and Related Developments
    • 7.14 Curis
      • 7.14.1 Curis Business Overview
      • 7.14.2 Curis Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
      • 7.14.3 Curis Drugs for Non-small Cell Lung Cancer Product Introduction
      • 7.14.4 Curis Response to COVID-19 and Related Developments
    • 7.15 CytRx
      • 7.15.1 CytRx Business Overview
      • 7.15.2 CytRx Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
      • 7.15.3 CytRx Drugs for Non-small Cell Lung Cancer Product Introduction
      • 7.15.4 CytRx Response to COVID-19 and Related Developments
    • 7.16 Eli Lilly
      • 7.16.1 Eli Lilly Business Overview
      • 7.16.2 Eli Lilly Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
      • 7.16.3 Eli Lilly Drugs for Non-small Cell Lung Cancer Product Introduction
      • 7.16.4 Eli Lilly Response to COVID-19 and Related Developments
    • 7.17 Exelixis
      • 7.17.1 Exelixis Business Overview
      • 7.17.2 Exelixis Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
      • 7.17.3 Exelixis Drugs for Non-small Cell Lung Cancer Product Introduction
      • 7.17.4 Exelixis Response to COVID-19 and Related Developments
    • 7.18 Fresenius Kabi
      • 7.18.1 Fresenius Kabi Business Overview
      • 7.18.2 Fresenius Kabi Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
      • 7.18.3 Fresenius Kabi Drugs for Non-small Cell Lung Cancer Product Introduction
      • 7.18.4 Fresenius Kabi Response to COVID-19 and Related Developments
    • 7.19 Genentech
      • 7.19.1 Genentech Business Overview
      • 7.19.2 Genentech Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
      • 7.19.3 Genentech Drugs for Non-small Cell Lung Cancer Product Introduction
      • 7.19.4 Genentech Response to COVID-19 and Related Developments
    • 7.20 Hikma Pharmaceuticals
      • 7.20.1 Hikma Pharmaceuticals Business Overview
      • 7.20.2 Hikma Pharmaceuticals Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
      • 7.20.3 Hikma Pharmaceuticals Drugs for Non-small Cell Lung Cancer Product Introduction
      • 7.20.4 Hikma Pharmaceuticals Response to COVID-19 and Related Developments
    • 7.21 Hospira
      • 7.21.1 Hospira Business Overview
      • 7.21.2 Hospira Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
      • 7.21.3 Hospira Drugs for Non-small Cell Lung Cancer Product Introduction
      • 7.21.4 Hospira Response to COVID-19 and Related Developments
    • 7.22 Intas Pharmaceuticals
      • 7.22.1 Intas Pharmaceuticals Business Overview
      • 7.22.2 Intas Pharmaceuticals Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
      • 7.22.3 Intas Pharmaceuticals Drugs for Non-small Cell Lung Cancer Product Introduction
      • 7.22.4 Intas Pharmaceuticals Response to COVID-19 and Related Developments
    • 7.23 Karyopharm Therapeutics
      • 7.23.1 Karyopharm Therapeutics Business Overview
      • 7.23.2 Karyopharm Therapeutics Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
      • 7.23.3 Karyopharm Therapeutics Drugs for Non-small Cell Lung Cancer Product Introduction
      • 7.23.4 Karyopharm Therapeutics Response to COVID-19 and Related Developments
    • 7.24 Kyowa Hakko Kirin
      • 7.24.1 Kyowa Hakko Kirin Business Overview
      • 7.24.2 Kyowa Hakko Kirin Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
      • 7.24.3 Kyowa Hakko Kirin Drugs for Non-small Cell Lung Cancer Product Introduction
      • 7.24.4 Kyowa Hakko Kirin Response to COVID-19 and Related Developments
    • 7.25 Ligand Pharmaceuticals
      • 7.25.1 Ligand Pharmaceuticals Business Overview
      • 7.25.2 Ligand Pharmaceuticals Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
      • 7.25.3 Ligand Pharmaceuticals Drugs for Non-small Cell Lung Cancer Product Introduction
      • 7.25.4 Ligand Pharmaceuticals Response to COVID-19 and Related Developments

    8 Key Findings

      9 Appendix

      • 9.1 About US

      This report covers market size and forecasts of Drugs for Non-small Cell Lung Cancer, including the following market information:
      Global Drugs for Non-small Cell Lung Cancer Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Drugs for Non-small Cell Lung Cancer Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Drugs for Non-small Cell Lung Cancer Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Drugs for Non-small Cell Lung Cancer Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)

      Key market players
      Major competitors identified in this market include Bristol-Myers Squibb, GlaxoSmithKline, Menarini, Sanofi, Ziopharm Oncology, Alchemia, Amgen, Apotex, BioMarin Pharmaceutical, CellAct Pharma, Cerulean Pharma, Cipla, Cornerstone Pharmaceuticals, Curis, CytRx, Eli Lilly, Exelixis, Fresenius Kabi, Genentech, Hikma Pharmaceuticals, Hospira, Intas Pharmaceuticals, Karyopharm Therapeutics, Kyowa Hakko Kirin, Ligand Pharmaceuticals, etc.

      Based on the Region:
      Asia-Pacific (China, Japan, South Korea, India and ASEAN)
      North America (US and Canada)
      Europe (Germany, France, UK and Italy)
      Rest of World (Latin America, Middle East & Africa)

      Based on the Type:
      Radiofrequency Ablation (RFA)
      Radiation Therapy
      Chemotherapy
      Targeted Therapies
      Immunotherapy

      Based on the Application:
      Hospitals
      Clinics
      Other



      Summary:
      Drugs for Non-small Cell Lung Cancer Market Research Report is about Drugs for Non-small Cell Lung Cancer Industry study. Get complete Drugs for Non-small Cell Lung Cancer market research report published after Market Study, Industrial Analysis with Trends & Statistics. Drugs for Non-small Cell Lung Cancer Market Report is a syndicated report for Investors and Manufacturer to understand Market Demand, Growth, trends and Factor Influencing market in upcoming years.



      REPORT YOU MIGHT BE INTERESTED